Healthcare provider profile · identity verified

Ashish Patel, M.D.

Hospitalist · DANVILLE, CA · NPI 1932413200

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Eliquis	Apixaban	168	47
Atorvastatin Calcium	Atorvastatin Calcium	146	58
Gabapentin	Gabapentin	122	48
Levothyroxine Sodium	Levothyroxine Sodium	116	42
Amlodipine Besylate	Amlodipine Besylate	87	41
Furosemide	Furosemide	73	26
Pantoprazole Sodium	Pantoprazole Sodium	73	32
Warfarin Sodium	Warfarin Sodium	57	suppressed
Tamsulosin Hcl	Tamsulosin Hcl	55	22
Metoprolol Tartrate	Metoprolol Tartrate	49	26
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	47	15
Lisinopril	Lisinopril	47	20
Donepezil Hcl	Donepezil Hcl	46	suppressed
Carvedilol	Carvedilol	45	18
Xarelto	Rivaroxaban	44	suppressed
Baclofen	Baclofen	43	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	42	suppressed
Trazodone Hcl	Trazodone Hcl	42	13
Mirtazapine	Mirtazapine	41	27
Potassium Chloride	Potassium Chloride	41	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	40	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	40	suppressed
Ipratropium-Albuterol	Ipratropium/Albuterol Sulfate	39	suppressed
Losartan Potassium	Losartan Potassium	39	16
Simvastatin	Simvastatin	38	suppressed
Ondansetron Hcl	Ondansetron Hcl	37	16
Atenolol	Atenolol	34	suppressed
Sertraline Hcl	Sertraline Hcl	34	suppressed
Metformin Hcl	Metformin Hcl	33	19
Breo Ellipta	Fluticasone/Vilanterol	32	suppressed
Oxycodone Hcl	Oxycodone Hcl	30	suppressed
Cephalexin	Cephalexin	29	13
Enoxaparin Sodium	Enoxaparin Sodium	29	suppressed
Rosuvastatin Calcium	Rosuvastatin Calcium	29	15
Metoprolol Succinate	Metoprolol Succinate	28	19
Amiodarone Hcl	Amiodarone Hcl	27	14
Cefpodoxime Proxetil	Cefpodoxime Proxetil	26	19
Glipizide	Glipizide	26	suppressed
Allopurinol	Allopurinol	25	suppressed
Heparin Sodium	Heparin Sodium,porcine	25	suppressed
Lactulose	Lactulose	25	suppressed
Renacidin	Citric Ac/Gluconolact/Mag Carb	25	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	24	suppressed
Clopidogrel	Clopidogrel Bisulfate	21	11
Escitalopram Oxalate	Escitalopram Oxalate	21	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	21	suppressed
Myrbetriq	Mirabegron	21	suppressed
Citalopram Hbr	Citalopram Hydrobromide	20	suppressed
Divalproex Sodium	Divalproex Sodium	20	suppressed
Klor-Con 10	Potassium Chloride	20	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	18	13
Tizanidine Hcl	Tizanidine Hcl	18	suppressed
Digoxin	Digoxin	17	suppressed
Fludrocortisone Acetate	Fludrocortisone Acetate	17	suppressed
Prednisone	Prednisone	17	suppressed
Flecainide Acetate	Flecainide Acetate	16	suppressed
Spironolactone	Spironolactone	16	suppressed
Copaxone	Glatiramer Acetate	15	suppressed
Duloxetine Hcl	Duloxetine Hcl	15	12
Lorazepam	Lorazepam	15	suppressed
Montelukast Sodium	Montelukast Sodium	15	suppressed
Pregabalin	Pregabalin	15	suppressed
Sodium Chloride	0.9 % Sodium Chloride	15	suppressed
Acetazolamide	Acetazolamide	14	suppressed
Buspirone Hcl	Buspirone Hcl	14	suppressed
Hydrochlorothiazide	Hydrochlorothiazide	14	suppressed
Jardiance	Empagliflozin	14	suppressed
Pravastatin Sodium	Pravastatin Sodium	14	suppressed
Tramadol Hcl	Tramadol Hcl	14	suppressed
Memantine Hcl Er	Memantine Hcl	13	suppressed
Phenytoin Sodium Extended	Phenytoin Sodium Extended	13	suppressed
Probenecid	Probenecid	13	suppressed
Ropinirole Hcl	Ropinirole Hcl	13	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	13	suppressed
Brilinta	Ticagrelor	12	suppressed
Carbidopa-Levodopa Er	Carbidopa/Levodopa	12	suppressed
Clonazepam	Clonazepam	12	suppressed
Ezetimibe	Ezetimibe	12	suppressed
Finasteride	Finasteride	12	suppressed
Hydralazine Hcl	Hydralazine Hcl	12	suppressed
Latanoprost	Latanoprost	12	suppressed
Midodrine Hcl	Midodrine Hcl	12	suppressed
Omeprazole	Omeprazole	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error